Skip to main content

Table 1 Characteristics of CN-AML in this study

From: Development and validation of a novel circular RNA as an independent prognostic factor in acute myeloid leukemia

Variable

Training group

Validated group

P value

Number

60

218

 

Sex, male, n (%)

32 (53.3)

127 (58.3)

0.556

Age, median (range), years

48.00 [37.75, 53.00]

52.50 [39.00, 63.00]

0.001

WBC, median (IQR), × 109/L

19.05 [7.87, 40.23]

14.20 [3.70, 60.02]

0.746

HB, median (IQR), g/L

84.00 [69.00, 97.00]

84.50 [67.00, 103.75]

0.760

PLT, median (IQR), × 109/L

40.00 [27.00, 65.00]

48.00 [25.25, 85.50]

0.225

BM blast, median (IQR), %

63.00 [44.00, 81.75]

68.25 [43.25, 83.38]

0.367

FAB classification, n (%)

  

0.674

 M0

5 (8.3)

26 (11.9)

 

 M1

7 (11.7)

24 (11.0)

 

 M2

26 (43.3)

103 (47.2)

 

 M4

4 (6.7)

9 (4.1)

 

 M5

17 (28.3)

55 (25.2)

 

 M6

1 (1.7)

1 (0.5)

 

Gene mutations, n (%)

 FLT3-ITD

14 (23.3)

45 (20.6)

0.722

 NPM1

17 (28.3)

54 (25.8)

0.740

 CEBPADM

4 (6.7)

34 (16.8)

0.060

 DNMT3A

8 (13.3)

28 (13.9)

1.000

 IDH1

12 (20.0)

32 (16.0)

0.556

 IDH2

11 (18.3)

24 (12.6)

0.288

ENL favorable group

17 (28.3)

59 (27.1)

0.871

  1. European LeukemiaNet (ELN) favorable genotype represents NPM1 mutant and FLT3-ITD negative or double allele CEBPA mutations
  2. WBC white blood cell count, HB hemoglobin, PLT platelet count, BM bone marrow, FAB Franch-American-British, DM double allele, IQR interquartile range